Aleksi Tornio
aleksi.tornio@utu.fi +358 29 450 4608 +358 50 476 5715 Kiinamyllynkatu 10 Turku ORCID identifier: https://orcid.org/0000-0001-5713-5692 |
Areas of expertise
Clinical Pharmacology; Pharmacokinetics; Drug-drug interactions; Pharmacogenetics
Clinical Pharmacology; Pharmacokinetics; Drug-drug interactions; Pharmacogenetics
Publications 
5 of 5
- The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: Evidence for mechanism-based inhibition of CYP2C8 in vivo (2008)
- Clinical Pharmacology and Therapeutics
(A1 Refereed original research article in a scientific journal) - Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone (2008)
- Drug Metabolism and Disposition
(A1 Refereed original research article in a scientific journal) - Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen (2007)
- European Journal of Clinical Pharmacology
(A1 Refereed original research article in a scientific journal) - Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide (2006)
- European Journal of Clinical Pharmacology
(A1 Refereed original research article in a scientific journal) - The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone (2006)
- European Journal of Clinical Pharmacology
(A1 Refereed original research article in a scientific journal) - Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P4502C8 (2005)
- Basic and Clinical Pharmacology and Toxicology
(A1 Refereed original research article in a scientific journal)
UTU Research Portal